Cogent Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cogent Biosciences
COGT Stock  USD 35.52  1.60  4.31%   
Analyzing historical trends in various income statement and balance sheet accounts from Cogent Biosciences' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cogent Biosciences' valuation are summarized below:
Gross Profit
-121.6 M
Market Capitalization
5.5 B
Enterprise Value Revenue
925.407
Earnings Share
(2.05)
Quarterly Revenue Growth
(1.00)
There are currently one hundred twenty fundamental signals for Cogent Biosciences that can be evaluated and compared over time across rivals. All traders should validate Cogent Biosciences' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 765.5 M in 2026. Enterprise Value is likely to gain to about 689.3 M in 2026

Cogent Biosciences Total Revenue

0.0

Check Cogent Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cogent Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.3 M, Interest Expense of 4.8 M or Selling General Administrative of 52.3 M, as well as many indicators such as Price To Sales Ratio of 35.83, Dividend Yield of 0.0 or PTB Ratio of 3.58. Cogent financial statements analysis is a perfect complement when working with Cogent Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Cogent Stock
Check out the analysis of Cogent Biosciences Correlation against competitors.
For more information on how to buy Cogent Stock please use our How to Invest in Cogent Biosciences guide.

Cogent Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets195.8 M377.1 M166.3 M
Slightly volatile
Other Current Liabilities50.9 M48.5 M13.2 M
Slightly volatile
Total Current Liabilities67.3 M64.1 M22.6 M
Slightly volatile
Total Stockholder Equity160.7 M294.7 M133.2 M
Slightly volatile
Property Plant And Equipment Net32.1 M30.5 M11.4 M
Slightly volatile
Current Deferred Revenue31 M29.5 M10.8 M
Slightly volatile
Accounts Payable14.5 M13.8 M4.5 M
Slightly volatile
Cash110.7 M112.9 M99 M
Pretty Stable
Non Current Assets Total37.9 M36.1 M14.6 M
Slightly volatile
Cash And Short Term Investments174.9 M330.1 M149.8 M
Slightly volatile
Common Stock Shares Outstanding125.4 M119.4 M35.9 M
Slightly volatile
Liabilities And Stockholders Equity195.8 M377.1 M166.3 M
Slightly volatile
Non Current Liabilities Total11.3 M18.3 M13.1 M
Pretty Stable
Other Current Assets11.3 M10.8 M3.1 M
Slightly volatile
Other Stockholder Equity1.2 B1.2 B341.8 M
Slightly volatile
Total Liabilities86.5 M82.4 M36.1 M
Slightly volatile
Total Current Assets178.7 M340.9 M152.9 M
Slightly volatile
Short Term Debt2 M1.8 M1.3 M
Slightly volatile
Common Stock132.8 K126.5 K44.4 K
Slightly volatile
Non Currrent Assets Other3.1 M5.6 M2.5 M
Slightly volatile
Common Stock Total Equity84.5 K80.5 K34.8 K
Slightly volatile
Property Plant And Equipment Gross39.5 M37.6 M13.7 M
Slightly volatile
Inventory60 K67.5 K73.7 K
Slightly volatile
Net Working Capital173.7 M276.9 M113.7 M
Slightly volatile
Capital Stock68.1 M127.3 M37 M
Slightly volatile
Short and Long Term Debt Total12.9 M20.1 M9.3 M
Slightly volatile
Net Tangible Assets130.4 M218.4 M87.6 M
Slightly volatile
Other Assets4.8 M5.5 M3.1 M
Slightly volatile
Capital Lease Obligations12.9 M20.1 M9.3 M
Slightly volatile
Property Plant Equipment4.3 M7 M6.6 M
Slightly volatile
Capital Surpluse485.2 M691.3 M407.5 M
Slightly volatile
Preferred Stock Total Equity69.9 M59.2 M96 M
Slightly volatile

Cogent Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.3 M5 M1.9 M
Slightly volatile
Selling General Administrative52.3 M49.8 M16.8 M
Slightly volatile
Other Operating Expenses333.2 M317.3 M98 M
Slightly volatile
Research Development280.9 M267.6 M81.2 M
Slightly volatile
Total Operating Expenses333.2 M317.3 M96.5 M
Slightly volatile
Net Interest Income21.8 M20.8 M4.7 M
Slightly volatile
Interest Income21.8 M20.8 M4.7 M
Slightly volatile
Total Other Income Expense Net24.2 M23.1 M6.5 M
Slightly volatile
Reconciled Depreciation2.6 M5 M2 M
Slightly volatile
Cost Of Revenue5.3 M4 M2.9 M
Slightly volatile
Non Operating Income Net Other6.7 M8.7 M7.2 M
Very volatile
Selling And Marketing Expenses27.5 M30.9 M33.7 M
Slightly volatile

Cogent Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation48 M45.7 M12.4 M
Slightly volatile
Begin Period Cash Flow101.2 M61.2 M65.2 M
Slightly volatile
Depreciation5.3 M5 M1.8 M
Slightly volatile
Capital Expenditures626 K659 K1.8 M
Very volatile
End Period Cash Flow111.2 M112.9 M99.3 M
Pretty Stable
Issuance Of Capital Stock138.1 M245.3 M108 M
Slightly volatile
Change To Netincome21.1 M21.1 M10.8 M
Slightly volatile
Sale Purchase Of Stock1.4 M1.5 M81 M
Slightly volatile
Change Receivables1.6 M1.8 M2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio35.8318.1844.0242
Slightly volatile
PTB Ratio3.583.633.4395
Pretty Stable
Days Sales Outstanding35.2729.236.8738
Pretty Stable
Book Value Per Share2.72.848.2449
Slightly volatile
Stock Based Compensation To Revenue0.720.690.4196
Slightly volatile
Capex To Depreciation0.140.155.7529
Slightly volatile
PB Ratio3.583.633.4395
Pretty Stable
Payables Turnover33.2331.6514.1661
Slightly volatile
Sales General And Administrative To Revenue2.091.991.3516
Slightly volatile
Research And Ddevelopement To Revenue8.728.315.2854
Slightly volatile
Capex To Revenue0.00160.00170.2767
Slightly volatile
Cash Per Share3.023.1810.1021
Slightly volatile
Days Payables Outstanding11.3411.9415.6 K
Slightly volatile
Net Debt To EBITDA0.320.346.026
Slightly volatile
Current Ratio6.774.799.3314
Slightly volatile
Tangible Book Value Per Share2.72.848.2449
Slightly volatile
Receivables Turnover7.0610.129.9042
Very volatile
Shareholders Equity Per Share2.72.848.2449
Slightly volatile
Debt To Equity0.08160.07840.1361
Slightly volatile
Capex Per Share0.0060.00630.1813
Slightly volatile
Graham Net Net2.272.397.5207
Slightly volatile
Revenue Per Share1.060.640.8849
Pretty Stable
Interest Debt Per Share0.180.190.5673
Slightly volatile
Debt To Assets0.06150.06130.0916
Slightly volatile
Operating Cycle35.2729.236.8738
Pretty Stable
Price Book Value Ratio3.583.633.4395
Pretty Stable
Days Of Payables Outstanding11.3411.9415.6 K
Slightly volatile
Ebt Per Ebit1.051.070.9625
Slightly volatile
Company Equity Multiplier1.461.471.3584
Pretty Stable
Total Debt To Capitalization0.07320.07340.1166
Slightly volatile
Debt Equity Ratio0.08160.07840.1361
Slightly volatile
Quick Ratio6.774.799.331
Slightly volatile
Net Income Per E B T0.760.860.9344
Slightly volatile
Cash Ratio1.932.037.674
Slightly volatile
Days Of Sales Outstanding35.2729.236.8738
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.90.9654
Pretty Stable
Price To Book Ratio3.583.633.4395
Pretty Stable
Fixed Asset Turnover1.661.491.6718
Slightly volatile
Debt Ratio0.06150.06130.0916
Slightly volatile
Price Sales Ratio35.8318.1844.0242
Slightly volatile
Asset Turnover0.02680.02820.072
Very volatile
Price Fair Value3.583.633.4395
Pretty Stable

Cogent Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap765.5 M729.1 M384.2 M
Slightly volatile

Cogent Fundamental Market Drivers

Cogent Upcoming Events

12th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cogent Biosciences Financial Statements

Cogent Biosciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Cogent Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Cogent Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cogent Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue29.5 M31 M
Cost Of Revenue4 M5.3 M
Stock Based Compensation To Revenue 0.69  0.72 
Sales General And Administrative To Revenue 1.99  2.09 
Research And Ddevelopement To Revenue 8.31  8.72 
Revenue Per Share 0.64  1.06 
Ebit Per Revenue(12.01)(11.41)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cogent Stock Analysis

When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY